GSK plc (NYSE:GSK) Stock Holdings Lifted by Corient Private Wealth LLC

Corient Private Wealth LLC lifted its holdings in GSK plc (NYSE:GSK) by 12.8% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 96,344 shares of the pharmaceutical company’s stock after buying an additional 10,895 shares during the quarter. Corient Private Wealth LLC’s holdings in GSK were worth $3,258,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of GSK. United Bank lifted its position in shares of GSK by 7.3% in the 3rd quarter. United Bank now owns 25,785 shares of the pharmaceutical company’s stock worth $1,054,000 after buying an additional 1,760 shares during the last quarter. Thrivent Financial for Lutherans lifted its position in GSK by 3.4% in the 3rd quarter. Thrivent Financial for Lutherans now owns 53,348 shares of the pharmaceutical company’s stock valued at $2,181,000 after purchasing an additional 1,737 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in GSK by 13.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 121,603 shares of the pharmaceutical company’s stock valued at $4,971,000 after purchasing an additional 14,687 shares during the last quarter. Raymond James Trust N.A. lifted its position in GSK by 6.9% in the 3rd quarter. Raymond James Trust N.A. now owns 45,948 shares of the pharmaceutical company’s stock valued at $1,878,000 after purchasing an additional 2,969 shares during the last quarter. Finally, Nwam LLC bought a new stake in GSK in the 3rd quarter valued at about $625,000. 15.74% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 7th. Morgan Stanley assumed coverage on shares of GSK in a research report on Wednesday, February 12th. They set an “equal weight” rating on the stock. Seven investment analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Stock Down 0.5 %

GSK stock opened at $39.22 on Friday. GSK plc has a 52-week low of $31.72 and a 52-week high of $45.93. The company’s 50 day simple moving average is $36.66 and its 200-day simple moving average is $36.92. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. The firm has a market capitalization of $81.18 billion, a P/E ratio of 24.67, a P/E/G ratio of 1.12 and a beta of 0.58.

GSK (NYSE:GSK) last released its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. As a group, equities research analysts anticipate that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be given a dividend of $0.3932 per share. The ex-dividend date of this dividend is Friday, February 21st. This is an increase from GSK’s previous quarterly dividend of $0.39. This represents a $1.57 dividend on an annualized basis and a yield of 4.01%. GSK’s payout ratio is presently 98.74%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.